Dermapharm's Q4 performance falls short of expectations

LootboxPhobia · 2026-03-10T08:54:44+00:00

Dermapharm Holding SE releases preliminary results for Q4 2025 and the full year, with Q4 sales of €296 million, up 2% year-over-year, below expectations. Full-year sales totaled €1.165 billion, down 1% year-over-year. Adjusted EBITDA increased by 3%, but also fell short of consensus expectations. The profit margin improvement was driven by product optimization and the reduction of loss-making businesses.

LootboxPhobia

2026-03-10 08:54:44

Abstract generation in progress

Investing.com – Dermapharm Holding SE (ETR:DMP) announced preliminary results for Q4 2025 and the full year on Tuesday, with figures at the lower end of the company’s guidance.

The German pharmaceutical company reported Q4 sales of €296 million, up 2% year-over-year. This figure was 6% below the consensus estimate of €313 million compiled by the company.

Adjusted EBITDA for the quarter reached €89 million, up 18% year-over-year, but 2% below the consensus estimate of €91 million.

The adjusted EBITDA margin expanded from 25.9% in the same period last year to 30.0%, the highest level since Q1 2023.

For the full year 2025, Dermapharm reported sales of €1.165 billion, down 1% from the previous year and 1% below the consensus estimate of €1.183 billion.

Full-year adjusted EBITDA was €325 million, up 3% year-over-year, with a profit margin of 27.9%, compared to 26.7% in 2024. This figure was 1% below the consensus estimate of €327 million.

The increase in the full-year profit margin was driven by product portfolio optimization and the gradual phase-out of unprofitable parallel import activities. The company plans to release audited results and provide guidance for 2026 on March 31.

This article was translated with the assistance of artificial intelligence. For more information, please see our Terms of Use.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.